Small Stocks, Big Money™

GreenPower Motor Company (NASDAQ: GP) has introduced the EV Star REEFERX, a fully customizable all-electric refrigerated medium-duty delivery truck. Built on the EV Star Cab & Chassis platform, the REEFERX offers increased payload capacity of up to 5,500 lbs, a range of up to 150 miles, and features multi-temperature zones ideal for transporting fresh and frozen goods, flowers, and pharmaceuticals. The innovative one-piece box design ensures seamless sanitation and consistent insulation, enhancing durability and efficiency. With the market for refrigerated trucks expected to grow significantly, GP is positioned to meet the rising demand with this versatile, zero-emission solution.

Zomedica Corp. (NYSE American: ZOM) completed a significant expansion of its global manufacturing and distribution facility in Roswell, Georgia. The facility now spans 18,400 sq. ft., adding 6,000 sq. ft. of space to enhance warehousing and sales order fulfillment, while increasing manufacturing capacity five-fold. "Our expanded Roswell facility will drive improved efficiencies in warehousing and order fulfillment," said Tony Blair, EVP and COO. CEO Larry Heaton highlighted the timely expansion aligning with rapid sales growth, strengthening ZOM's ability to meet growing customer demand with efficient production and distribution.

Alta Global Group (NYSE American: MMA) announced a strategic partnership with Eric Nicksick, esteemed coach of UFC champions Francis Ngannou, Aljamain Sterling, and Sean Strickland. This alliance aims to advance MMA's mission to convert 640 million fans into active participants, with the collaboration enhancing Alta's presence in North America and supporting subscription sales growth. Alta's CEO, Nick Langton, and VP Rich Chou emphasized Nicksick's role in boosting gym partnerships and expanding the sport's reach. Alta is targeting 45,000 potential gym partners in the US.

Nexalin Technology (Nasdaq: NXL; NXLIW) received FDA consensus on the design of its clinical studies in anxiety and insomnia for the Gen-3 HALO Clarity™, a non-invasive headset device designed to address the global mental health epidemic. Set to begin in Q3 2024, the studies will involve 75 patients each for active and sham treatments to evaluate HALO’s efficacy. Following positive prior results, Nexalin aims to submit a De Novo request to the FDA for marketing approval. CEO Mark White highlighted HALO’s potential to revolutionize mental health care by offering a non-pharmacological treatment managed through a virtual clinic model, emphasizing remote monitoring and patient convenience.